Aerie Pharmaceuticals, Inc. (AERI): Price and Financial Metrics
Aerie Pharmaceuticals, Inc. (AERI)
Today's Latest Price: $14.03 USD
0.19 (-1.34%)
Updated May 29 4:00pm
Add AERI to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AERI Stock Summary
- With a year-over-year growth in debt of 1,131.41%, Aerie Pharmaceuticals Inc's debt growth rate surpasses 98.01% of about US stocks.
- As for revenue growth, note that AERI's revenue has grown 126.58% over the past 12 months; that beats the revenue growth of 95.62% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AERI comes in at -47.23% -- higher than that of just 9.87% of stocks in our set.
- Stocks that are quantitatively similar to AERI, based on their financial statements, market capitalization, and price volatility, are ARLO, DMRC, ORGS, XXII, and PSTG.
- AERI's SEC filings can be seen here. And to visit Aerie Pharmaceuticals Inc's official web site, go to www.aeriepharma.com.
AERI Daily Price Range
AERI 52-Week Price Range
AERI Stock Price Chart More Charts
AERI Price/Volume Stats
| Current price | $14.03 | 52-week high | $39.34 |
| Prev. close | $14.22 | 52-week low | $10.80 |
| Day low | $13.34 | Volume | 1,813,902 |
| Day high | $14.48 | Avg. volume | 976,823 |
| 50-day MA | $14.40 | Dividend yield | N/A |
| 200-day MA | $19.17 | Market Cap | 651.95M |
Aerie Pharmaceuticals, Inc. (AERI) Company Bio
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company was founded in 2005 and is based in Irvine, California.
Loading social stream, please wait...